Managing cow's milk protein allergy during the 2022 formula shortage: decision-making among pediatric healthcare providers

IF 3.3 Q2 ALLERGY

Frontiers in allergy Pub Date : 2024-05-22 DOI:10.3389/falgy.2024.1359103

Lea Oliveros, Jerry M. Brown, A. Fabbrini, A. Farrar, Luke Lamos, J. Florio, Jesse Beacker, Jessica V Baran, Michael J Wilsey

{"title":"Managing cow's milk protein allergy during the 2022 formula shortage: decision-making among pediatric healthcare providers","authors":"Lea Oliveros, Jerry M. Brown, A. Fabbrini, A. Farrar, Luke Lamos, J. Florio, Jesse Beacker, Jessica V Baran, Michael J Wilsey","doi":"10.3389/falgy.2024.1359103","DOIUrl":null,"url":null,"abstract":"Cow's milk protein allergy (CMPA) affects 2%-7% of infants and is managed with hypoallergenic formulas. The 2022 recalls of infant formulas due to factors including contamination led to specialty formula shortages, highlighting CMPA management challenges. Understanding healthcare providers' (HCPs) decision-making in transitioning to alternative formulas during shortages is crucial. Limited attention has been given to how pediatric physicians make these choices.This study utilized US HCPs' de-identified survey data to assess driving factors when switching extensively hydrolyzed formulas during shortages.104 eligible HCPs participated, including general pediatrics, pediatric allergy/immunology, and pediatric gastroenterology specialists. Safety, tolerability, and efficacy were identified as top factors for switching formulas. Formula 1 was considered well-tolerated, patient-accepted, and safe by all HCPs. Most expressed strong belief in Formula 1's safety and effectiveness.Findings inform CMPA management during shortages, offering guidance to HCPs for suitable formula selection and enhanced infant care.","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/falgy.2024.1359103","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Cow's milk protein allergy (CMPA) affects 2%-7% of infants and is managed with hypoallergenic formulas. The 2022 recalls of infant formulas due to factors including contamination led to specialty formula shortages, highlighting CMPA management challenges. Understanding healthcare providers' (HCPs) decision-making in transitioning to alternative formulas during shortages is crucial. Limited attention has been given to how pediatric physicians make these choices.This study utilized US HCPs' de-identified survey data to assess driving factors when switching extensively hydrolyzed formulas during shortages.104 eligible HCPs participated, including general pediatrics, pediatric allergy/immunology, and pediatric gastroenterology specialists. Safety, tolerability, and efficacy were identified as top factors for switching formulas. Formula 1 was considered well-tolerated, patient-accepted, and safe by all HCPs. Most expressed strong belief in Formula 1's safety and effectiveness.Findings inform CMPA management during shortages, offering guidance to HCPs for suitable formula selection and enhanced infant care.

查看原文本刊更多论文

2022 年配方奶粉短缺期间的牛奶蛋白过敏管理：儿科医疗服务提供者的决策

2%-7%的婴儿会对牛奶蛋白过敏（CMPA），可通过低敏配方奶粉进行控制。由于污染等因素，2022 年婴儿配方奶粉召回导致特殊配方奶粉短缺，凸显了 CMPA 管理方面的挑战。了解医疗保健提供者（HCP）在短缺期间过渡到替代配方奶粉的决策至关重要。本研究利用美国医疗保健提供者的去标识化调查数据来评估在配方奶粉短缺期间转换广泛水解配方奶粉的驱动因素。104 位符合条件的医疗保健提供者参与了本研究，其中包括普通儿科、儿科过敏/免疫科和儿科胃肠病学专家。安全性、耐受性和有效性被认为是更换配方奶粉的首要因素。所有 HCP 都认为配方 1 具有良好的耐受性、患者接受度和安全性。研究结果为短缺期间的 CMPA 管理提供了参考，为 HCP 选择合适的配方奶粉和加强婴儿护理提供了指导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊